Subscribe for Free (RSS + E-mail)

RSS + E-mail

Incubator Guide →
Featured▾
- Incubator Guide →
Xconomy National
Xperience
Tech + Life▾
- View More in Xperience ›
Our
Cities▾
Tech
Channels ▾
Meet the
Xconomists ▾
Our
Events ▾

ltimmerman

Luke Timmerman

Luke is an award-winning journalist specializing in life sciences. Before joining Xconomy, he was the U.S. biotechnology reporter for Bloomberg News, based in San Francisco. There, he led coverage of major medical meetings and broke news about the industry’s top companies. His stories appeared in The New York Times, Los Angeles Times, Boston Globe, and International Herald Tribune. Before that, his passionate coverage of biotechnology won many awards for The Seattle Times.

While at the Times, Luke was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award, the Sigma Delta Chi prize from the Society of Professional Journalists, the Society of American Business Editors and Writers award, an honorable mention Gerald Loeb Award, and was nominated for the Pulitzer Prize in public service. At Xconomy, he was honored in 2012 as a finalist for the Gerald Loeb Award, and received a SABEW award for biotech columns.

Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison. In 2005-2006, he was a Knight Science Journalism Fellow at MIT. In his spare time, Luke enjoys running, mountaineering, and fantasy baseball. Having grown up in Wisconsin, he is, naturally, a lifelong fan of the Green Bay Packers and the Wisconsin Badgers.

Recent posts

Cerulean Pharma Fails to Extend Lives in Lung Cancer Study

Cambridge, MA-based Cerulean Pharma spent a lot of time and money trying to get the answer to an important question—whether its new drug could extend the lives of terminally ill lung... Read more »
Enanta, Tetraphase Go Public in Boston Biotech IPO Madness

If Boston biotech were playing in this week’s NCAA men’s basketball tournament, it would have to be a No. 1 seed. It’s not every week that a region gets to claim... Read more »
AstraZeneca Shells Out $240M Upfront For Moderna mRNA Drugs

The new CEO of AstraZeneca, Pascal Soriot, has just written a huge check, worth $240 million in upfront cash. It’s going to a little biotech startup in Cambridge, MA, that... Read more »
Blueprint Medicines Combs Through Genome for the Next Gleevec(s)

Gleevec is like the proverbial shining city on the hill in the pharmaceutical business. When it was first approved in 2001, it beat the long odds of drug development, becoming... Read more »
Affymax Cuts 230 Jobs, Mulls Bankruptcy, After Drug Withdrawal

Big cuts were inevitable at Affymax the past few weeks, and confirmation came today.

Palo Alto, CA-based Affymax (NASDAQ: AFFY) said today that the company is cutting 230 people from... Read more »
Why Are Healthcare Costs Exploding? See Proton Cancer Therapy

Whenever a new medical technology comes out in the U.S., a few things happen. Doctors, hospitals, the media, and, of course, the drug and device makers cheer. Newer technology must always... Read more »
Allozyne Conducts Round of Employee ‘Furloughs’

Seattle-based Allozyne, one of the promising biotech drug developers to graduate from the venture-backed Accelerator, recently conducted a small round of employee furloughs.

Allozyne made the latest round of... Read more »
GlaxoSmithKline Shuts Down Sirtris, Five Years After $720M Buyout

[Updated 2:25 pm ET, 3/13/13] GlaxoSmithKline is closing down Cambridge, MA-based Sirtris Pharmaceuticals, almost five years after it paid $720 million to acquire the hot biotech with a... Read more »
Spiral Genetics, Maker of Software for the Genome, Gets $3M from DFJ

Spiral Genetics, the Seattle-based maker of software that helps crunch big volumes of DNA data, has just raised its first sizable round of venture capital.

Spiral is announcing today it... Read more »
IMS Health Acquires Appature to Get Healthcare Marketing Software

[Updated: 11:30 am PT] Seattle-based Appature, the maker of software for healthcare marketers, has graduated from scrappy startup into something much bigger.

Appature is announcing today that it... Read more »
Biotech for the Belt-Tightening Era: Last Chance For Early-Bird Tix

The explosion of healthcare spending affects everybody who pay taxes to support Medicare and Medicaid. It affects anyone who has a job that comes with healthcare benefits, which keep getting more... Read more »
Some Bold Baseball and Biotech Picks for the 2013 Season

Spring training is here. That means I get to spend days thinking and writing about biotech and nights dreaming about hard-throwing setup men with decent walks-plus-hits-allowed per inning pitched (WHIP... Read more »
Veracyte Wins Over UnitedHealth With Thyroid Cancer Diagnostic

South San Francisco-based Veracyte was built to provide clear diagnostic answers for patients with curious thyroid lumps that might be cancerous. It’s taken a lot of research to build a convincing... Read more »
Roger Perlmutter Returns to Merck, Looks to Biotech Future (Again)

Roger Perlmutter is heading back to Merck, after a decade away. This time around, he’s got a lot more experience knowing how to build a pharmaceutical pipeline.

The Whitehouse Station, NJ-based... Read more »
Boston Biotech Seizes the Momentum: Last Chance for Early Bird Tix

I live in Seattle, and recently had a couple conversations with well-known West Coast biotech executives about what they see happening in Boston.

“Clearly, Boston has taken the leadership role” among... Read more »
Cerulean Pharma Arrives at Turning Point With Cancer Drug

One day this month, Cambridge, MA-based Cerulean Pharma will get the answers to two important questions that few private, venture-backed biotech companies ever get far enough to answer.

It will find... Read more »
Presage Snags $13M from Celgene to Pick Winning Cancer Drug Combos

Seattle-based Presage Biosciences has found another big partner that thinks it can help separate the winners from the losers in early cancer drug development, before the really big bucks get wasted... Read more »
Someone Needs to Rank U.S. Biotech Hubs, For Real

[Updated: 11:40 am PT] It’s time for a challenge:

Will somebody please come out with a deeply researched and credible report that ranks U.S. regional biotech clusters, on the... Read more »
Paul Allen Gives $7.5M to Little-Known Scientists Dreaming Big

Just a few days after tech moguls Mark Zuckerberg and Sergey Brin gave a bunch of prize money to some of biotech’s biggest stars, along comes Paul Allen doing his own... Read more »
Kala Pharma, From MIT & Johns Hopkins, Grabs $11.5M for Eye Drugs

If you need an effective drug today for age-related macular degeneration, the leading cause of blindness in the elderly, you need to get an injection at the back of the eye.... Read more »

Page 3 of 168 « previous page · next page »